A partial length recombinant protein corresponding to extra cellular domain of CD20 was used as the immunogen for this antibody.
Alternative Synonym:
MS4A1||CD20
CD20 is clinically validated as an immunotherapy target for B-cell lymphomas and autoimmune diseases. CD20 consists of large, intracellular, amino- and carboxyterminal portions connected by 4 membrane-spanning domains. Its high expression on malignant B cells and its reported lack of shedding from the surfacemake CD20 an ideal target for antibody-mediated killing. Anti-CD20 antibodies are believed to mediate the therapeutic effect by activation of complement-dependent cytotoxicity (CDC) and largely by antibody-dependent cellular cytotoxicity exerted by recruitment of innate immune effector cells expressing the Fcgamma receptor IIIa.
Western blot analysis: 2-4 µg/ml FACS : 0.5 µg / 10 6 cells
Fig-1: Cell surface flow analysis of hCD20 on human PBMCs (Lymphocytes gated) using 0.5 µg/ 10 6 cells. Green represents isotype control (ABEOMICS), red represents anti-hCD20 antibody (10-4162). Goat anti-mouse PE conjugated secondary antibody (ABEOMICS) was used. (Cells were incubated with primary antibody for 45 min. then washed twice with FLOW Staining buffer (ABEOMICS) by centrifuging at 1100 rpm for 5 min, followed by 30 min incubation with conjugated secondary antibody. Data acquisition w
Fig-2: Western blot analysis of CD20. Anti-CD20 antibody (Clone: ABM46C7) was tested at 2 µg/ml on Raji and Ramos lysates.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
